Cordynick® (CORDINIK®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceNicorandilNicorandil
Similar drugsTo uncover
  • Cordynick®
    pills inwards 
    PIK-PHARMA, LLC     Russia
    • Dosage form: & nbsppills
    Composition:

    For the dosage of 10 mg:

    active substance: nicorandil 10 mg;

    Excipients: potato starch - 5 mg, microcrystalline cellulose - 84 mg, calcium stearate - 1 mg;

    for dosage of 20 mg:

    active substance: nicorandil 20 mg;

    Excipients: potato starch - 10 mg, microcrystalline cellulose - 168 mg, calcium stearate - 2 mg.

    Description:White tablets with a weak grayish-yellowish hue of color, round in shape, flat-cylindrical, with a bevel.
    Pharmacotherapeutic group:Antianginal agent - potassium channel activator
    ATX: & nbsp

    C.01.D.X   Other peripheral vasodilators for the treatment of heart disease

    C.01.D.X.16   Nicorandil

    Pharmacodynamics:Nicorandil has an antianginal effect, which is based on a combination of nitrate-like properties and the ability to open potassium channels. Due to the opening of potassium channels nicorandil causes hyperpolarization of the cell membrane, and the nitrate-like effect consists in an increase in the intracellular content of cyclic guanyl monophosphate. These pharmacological effects lead to relaxation of smooth muscle cells and cellular myocardial protection in ischemia.Hemodynamic effects are expressed in a balanced decrease in pre- and post-loading (in contrast to nitrates and blockers of "slow" calcium channels (BCC), which act mainly on pre- or postnagruzku, respectively). Taking into account the selective vasodilation of the coronary arteries, the burden on the ischemic myocardium is minimal. Nicorandil does not affect the contractility of the myocardium, practically does not change the heart rate (heart rate). Reduces systemic blood pressure (BP) by less than 10%, has a beneficial beneficial effect on cerebral circulation in patients with ischemic stroke. Nicorandil does not affect the lipid metabolism and glucose metabolism. Nicorandil it relieves an attack of angina with a decrease in the pain syndrome within 4-7 minutes after receiving under the tongue and its complete cupping within 12-17 minutes.
    Pharmacokinetics:

    Nicorandil quickly and completely absorbed from the gastrointestinal tract, reaching a maximum concentration in the blood plasma after 0.5-1 hour. It is not subject to intensive metabolism in the liver and has a half-life of 50 minutes. It is excreted mainly by the kidneys.

    Nicorandil slightly binds to blood plasma proteins. The free fraction in the blood plasma is about 75%.

    Pharmacokinetic parameters depend little on the age of the patient, the presence of concomitant liver or kidney pathology, and the concomitant therapy.

    Indications:

    - Closing of angina attacks;

    - prevention of attacks of stable angina pectoris (in combination with other antianginal drugs) and in monotherapy with intolerance to beta-blockers and BCCC.

    Contraindications:

    - Hypersensitivity to the drug;

    - Acute myocardial infarction (and within 3 months after);

    - cardiogenic shock, collapse;

    - unstable angina;

    - chronic heart failure of III or IV functional class according to NYHA classification;

    - pronounced bradycardia (heart rate less than 50 beats per minute);

    - atrioventricular blockade of II and III degree;

    - left ventricular failure with low filling pressure;

    - arterial hypotension (systolic blood pressure less than 100 mm Hg);

    - simultaneous use of phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil);

    - Pregnancy and the period of breastfeeding (see para.section "Application during pregnancy and during breast-feeding");

    - age under 18 years (efficiency and safety not established).

    Carefully:

    Violations rhythm of the heart, atrioventricular blockade of the I degree, angina of Prinzmetal, arterial hypotension, impaired renal and / or liver function, hypovolemia, pulmonary edema, occlusive glaucoma, hyperkalemia, anemia.

    Pregnancy and lactation:

    It is not recommended to use the drug during pregnancy and during breastfeeding because of the lack of clinical experience in this category of patients.

    Dosing and Administration:

    Inside. Drinking with water, take regardless of food intake.

    Prevention of attacks of stable angina (long-term therapy of stable angina).

    The drug is usually given in a dose of 10 to 20 mg 2 - 3 times a day. The recommended initial dose of the drug is 10 mg 2 times a day. The effective therapeutic dose of the drug is selected individually, depending on the severity and duration of the disease.

    The maximum daily dose is 80 mg.

    When a headache occurs, the initial dose may be reduced.

    Coping an attack of angina pectoris.

    The drug should be taken immediately with the first signs of an attack of angina: the drug in a dose of 20 mg is put under the tongue and kept until completely dissolved, without swallowing.

    Side effects:

    Cardiovascular system: palpitation, tachycardia, lowering blood pressure, "tides" of blood to the skin of the face, peripheral edema.

    central nervous system: weakness, headache (does not require drug cancellation, can be mitigated by lowering the initial dose of the drug), dizziness, tinnitus, insomnia.

    The digestive tract: nausea, vomiting, unpleasant sensations in the stomach, feeling of overflow in the stomach, stomatitis (extremely rare); in some cases, an increase in the activity of "hepatic" transaminases (alanine aminotransferase and aspartate aminotransferase), alkaline phosphatase.

    Hypersensitivity reactions: possible development of allergic reactions.

    Overdose:

    Symptoms: a marked decrease in blood pressure, tachycardia.

    Treatment: gastric lavage, the appointment of activated charcoal (especially in the first 2 hours after an overdose), maintaining the function of the cardiovascular system, elevated limb position, symptomatic and supportive therapy, intravenous calcium gluconate and dopamine. It is possible to use hemodialysis.

    Interaction:With simultaneous use with antidepressants, inhibitors of phosphodiesterase-5 (sildenafil, vardenafil, tadalafil), vasodilators, antihypertensive drugs, tricyclic antidepressants, diuretics, beta-adrenoblockers, monoamine oxidase (MAO) inhibitors and ethanol - enhance antianginal action.

    With the simultaneous reception of the drug with the drug sapropterine it is possible to lower blood pressure below normal.

    Special instructions:

    The drug should be canceled gradually.

    During the period of therapy with the drug, it is necessary to control blood pressure, ECG parameters, the content of potassium ions and sodium ions in the blood; it is possible to strengthen the existing violations of the rhythm of the heart.

    Effect on the ability to drive transp. cf. and fur:

    Care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased attention and speed of psychomotor reactions.

    Form release / dosage:

    Tablets 10 mg and 20 mg.

    Packaging:

    For FSUE PNKB and ZAO OKHFK.

    10 tablets per contour cell pack.

    For 10, 20 or 30 tablets in a can of polymer with a lid.

    The bank or 2, 3 or 6 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

    For OOO PIK-PHARMA PRO.

    10 tablets per contour cell pack. For 2, 3 or 6 contour squares, together with the instructions for use, are placed in a pack of cardboard.

    Storage conditions:

    In a dry, protected from light place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:

    2 years. Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-006552/09
    Date of registration:17.08.2009 / 07.09.2016
    Expiration Date:Unlimited
    The owner of the registration certificate:PIK-PHARMA, LLC PIK-PHARMA, LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspPIK-PHARMA LLC PIK-PHARMA LLC Russia
    Information update date: & nbsp04.02.2018
    Illustrated instructions
      Instructions
      Up